Patents Assigned to ITEOS THERAPEUTICS
  • Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
    Patent number: 10945994
    Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 16, 2021
    Assignees: Pfizer Inc., iTEOS THERAPEUTICS
    Inventors: Manfred Kraus, Sandra Cauwenberghs, Stefano Crosignani, Gregory Driessens
  • 3-indol substituted derivatives, pharmaceutical compositions and methods for use
    Patent number: 10544095
    Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 28, 2020
    Assignees: Pfizer Inc., iTeos Therapeutics
    Inventors: Sacha Ninkovic, Michael Raymond Collins, Stefano Crosignani, Andreas Maderna, Indrawan James McAlpine, Stephanie Anne Scales, Martin Wythes
  • Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
    Patent number: 10398679
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 3, 2019
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
    Patent number: 9949951
    Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 24, 2018
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • 3-indol substituted derivatives, pharmaceutical compositions and methods for use
    Patent number: 9873690
    Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 23, 2018
    Assignees: Pfizer Inc, iTeos Therapeutics
    Inventors: Sacha Ninkovic, Stefano Crosignani, Indrawan James McAlpine, Michael Raymond Collins, Stephanie Anne Scales, Andreas Maderna, Martin Wythes
  • 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
    Patent number: 9758505
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: September 12, 2017
    Assignee: iTeos Therapeutics
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
  • Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
    Patent number: 9603836
    Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: March 28, 2017
    Assignee: ITEOS THERAPEUTICS
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose